Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96MF7

UPID:
NSE2_HUMAN

ALTERNATIVE NAMES:
E3 SUMO-protein transferase NSE2; MMS21 homolog; Non-structural maintenance of chromosomes element 2 homolog

ALTERNATIVE UPACC:
Q96MF7; Q8N549

BACKGROUND:
The E3 SUMO-protein ligase NSE2, known for its alternative names such as MMS21 homolog, is integral to the SMC5-SMC6 complex, aiding in the repair of DNA double-strand breaks through homologous recombination. Its activity includes the sumoylation of key proteins involved in telomere maintenance and DNA repair, highlighting its essential role in maintaining genomic integrity.

THERAPEUTIC SIGNIFICANCE:
E3 SUMO-protein ligase NSE2's malfunction is associated with Seckel syndrome 10, characterized by growth retardation and intellectual disability. The protein's involvement in critical cellular processes underscores the potential for developing targeted therapies that could mitigate the effects of related genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.